Crizotinib-d9 (PF-02341066-d9) is a deuterium-labeled derivative of Crizotinib, designed for use as a stable isotope in chemical research. Crizotinib is an orally bioavailable, ATP-competitive inhibitor targeting ALK and c-Met, exhibiting IC50 values of 20 nM and 8 nM, respectively. It is known to effectively inhibit tyrosine phosphorylation of NPM-ALK and c-Met in cell-based assays, with IC50 values of 24 nM and 11 nM. Additionally, Crizotinib serves as a ROS1 inhibitor and demonstrates significant tumor growth inhibition, making it crucial for oncology research applications.
Crizotinib-d9 (PF-02341066-d9) is a deuterium-labeled derivative of Crizotinib, designed for use as a stable isotope in chemical research. Crizotinib is an orally bioavailable, ATP-competitive inhibitor targeting ALK and c-Met, exhibiting IC50 values of 20 nM and 8 nM, respectively. It is known to effectively inhibit tyrosine phosphorylation of NPM-ALK and c-Met in cell-based assays, with IC50 values of 24 nM and 11 nM. Additionally, Crizotinib serves as a ROS1 inhibitor and demonstrates significant tumor growth inhibition, making it crucial for oncology research applications.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
